However, our analysis revealed that a substantial portion of breast tumors that failed to undergo pCR display markers of TIS and downregulate NOXA, hinting that both these processes might be implicated in mediating therapy resistance. The gene discussed is PMAIP1; the disease is breast neoplasm.